Novartis now expects its core operating profit to grow in the mid to high teens, after second-quarter results outpaced analysts’ expectations, boosted by revenue from its blockbuster treatments.
Novartis now expects its core operating profit to grow in the mid to high teens, after second-quarter results outpaced analysts’ expectations, boosted by revenue from its blockbuster treatments.
